BPC-157 + TB-500 (Wolverine Stack)
BPC-157 + TB-500 (Wolverine Stack), also written BPC 157 + TB 500, is supplied by White Label Peptides as a lyophilised powder in multi-dose vials, for laboratory and research use, to business buyers only. It sits in our recovery and repair category. Every batch is verified by HPLC and ships with its own Certificate of Analysis.
| Form | Lyophilised powder (vials) or ready-to-use solution (pre-filled pens) |
|---|---|
| Presentation | Vials: 5+5 mg, 10+10 mg. Pre-filled pens: 10+10 mg |
| Reconstitution | Typically reconstituted using: Bacteriostatic water - Sterile laboratory-grade water |
| Storage | Store refrigerated at 2-8°C in a cool, dry environment away from direct sunlight. Long-term storage may require freezing conditions prior to reconstitution. |
| Bpc157 Appearance | White to off-white lyophilised powder prior to reconstitution |
| Bpc157 Classification | Gastric-Derived Protective Peptide Fragment |
| Bpc157 Compound Name | BPC-157 |
| Bpc157 Full Name | Body Protection Compound-157 |
| Bpc157 Molecular Formula | C62H98N16O22 |
| Bpc157 Molecular Weight | Approximately 1419.5 g/mol |
| Bpc157 Peptide Type | Synthetic Pentadecapeptide |
| Bpc157 Sequence | GEPPPGKPADDAGLV |
| Tb500 Appearance | White to off-white lyophilised powder prior to reconstitution |
| Tb500 Classification | Thymosin Beta-4 Analogue |
| Tb500 Compound Name | TB-500 |
| Tb500 Full Name | Thymosin Beta-4 Fragment |
| Tb500 Molecular Formula | C212H350N56O78S |
| Tb500 Molecular Weight | Approximately 4963 g/mol |
| Tb500 Peptide Type | Synthetic Peptide Fragment |
| Tb500 Structure | TB-500 is a synthetic peptide version of the active region of Thymosin Beta-4, a naturally occurring peptide involved in cellular migration and tissue-related research processes. |
| Also written | BPC 157 + TB 500, BPC 157 + TB 500 peptide |
Specification data is provided for identification and procurement. It is not dosing guidance and it is not a claim of any effect.
Evidence and status
- Lab work
- Animal studies
- Human studies
- Approved label
Reviewed 2026-09-02. Regulatory status is stated for procurement and varies by market. It is not legal advice.
Research
What the published literature examined
Nothing has examined this combination. The published work on the two constituents is separate and is set out in full on their own pages: BPC-157 reaches human studies, TB-500 reaches animal studies and has been examined mainly as a doping-control analyte rather than as a therapeutic candidate. No study in any species has administered the two together, and no pharmacokinetic work describes how either behaves in the presence of the other. The blend is a packaging decision, and the literature behind it is two literatures that have never met.
What is not established
Everything specific to the combination. There is no interaction data, no combined pharmacokinetics, no combined safety work and no dose-finding for the pair. Evidence does not carry across from two constituents to their mixture, so a reader who treats the constituent literature as evidence for this product is reading about something that was never tested. Both constituents separately also lack human safety data at the quantities supplied here.
What distinguishes BPC-157 + TB-500 (Wolverine Stack)
It is a blend rather than a molecule, and that decides what can honestly be said about it. Both constituents are separately catalogued and separately documented here, so a buyer can read each evidence base in full and then see in one line that nothing joins them. The catalogue keeps the blend and its constituents as distinct products for the same reason CJC-1295 is listed twice: collapsing different materials onto one page is what vendor documentation does, and it is what makes vendor documentation unusable for procurement.
Sources
- US FDA. Briefing document, Pharmacy Compounding Advisory Committee, evaluation of BPC-157-related bulk drug substances, 11 May 2026
- US FDA. Briefing document, Pharmacy Compounding Advisory Committee: evaluation of TB-500-related bulk drug substances, 15 May 2026
- Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal. 2012;4(9):733-8
- ClinicalTrials.gov. NCT02637284, phase 1 safety and pharmacokinetics of BPC-157
- World Anti-Doping Agency. 2026 Prohibited List, sections S0 and S2.3
This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.
Specification
About this compound
The specification below is the batch-independent data. Purity and analysis date vary by batch, so they appear on the certificate issued with your order rather than on this page.
What this compound is
BPC-157 + TB-500 (Wolverine Stack) in supply terms
The Wolverine Stack is a pre-blended vial combining two separately catalogued compounds: BPC-157, a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV, C62H98N16O22, approximately 1419.5 g/mol), and TB-500, a synthetic fragment of Thymosin Beta-4 (C212H350N56O78S, approximately 4963 g/mol). Each retains its own molecular identity within the vial; blending combines two independently defined peptides into a single fill rather than creating a new chemical entity. This has direct specification consequences. A pre-blended vial should carry documentation covering both source compounds individually, not a single combined figure, since the two peptides differ in molecular weight, formula and classification (BPC-157 as a gastric-derived fragment, TB-500 as a Thymosin Beta-4 analogue). Buyers requesting Certificates of Analysis for a blend should confirm the paperwork verifies both components separately, batch by batch, rather than a single blended-product test. Presentation is a lyophilised powder in multi-dose research vials for injectable research format, white to off-white before reconstitution, with labelled content of BPC-157 10mg plus TB-500 10mg per vial. Reconstitution is typically carried out using bacteriostatic water or sterile laboratory-grade water. Storage requires refrigeration at 2-8C away from direct sunlight, with freezing recommended for extended holds prior to reconstitution.
This section describes the compound as a material. It makes no claim about any effect and is not guidance on use.
What varies by batch
The page identifies the compound. The certificate records the batch.
Purity, method, analysis date and issuing party belong on the batch record rather than in page copy.
| Send the volume you need for BPC-157 + TB-500 (Wolverine Stack) and your delivery country. We will quote against it. | Request pricing |
Questions
Supply, answered
Is BPC-157 + TB-500 (Wolverine Stack) available for private label?
Yes. It can be supplied under your own brand on the vial and the carton, with the Certificate of Analysis issued under your product name.
What is the minimum order quantity?
Set for this compound specifically and confirmed at the enquiry stage, before you commit.
What purity is supplied?
98 percent or higher, verified by HPLC. The certificate issued with your batch carries the actual figure for that batch.
How is it shipped?
As lyophilised powder in multi-dose vials, packed for transit. Delivery in 5 to 7 days once the batch is released.
We already buy BPC-157 + TB-500 (Wolverine Stack). Can you quote against our current volume?
Yes. Send the volume and the delivery country. Pricing is tiered per compound, so the quote reflects what you buy rather than a list price.
Can you supply BPC-157 + TB-500 (Wolverine Stack) as a second source?
Yes. Terms are agreed per compound, so you can add BPC-157 + TB-500 (Wolverine Stack) without moving anything else you buy elsewhere.
Request pricing for BPC-157 + TB-500 (Wolverine Stack)
Indicative volume and delivery country is enough to start. We reply within one working day.